Company news
Nuformix Plc (LSE:NFX) news
Nuformix Plc news releases on 6ix. Latest, Aug 1, 2019: Annual Financial Report
Press releases — page 3
Annual Financial Report
August 1, 2019
Final Results
July 18, 2019
Positive Results for NXP001 Clinical Trial
May 30, 2019
Holding(s) in Company - Amendment
May 28, 2019
Loan Conversion
May 24, 2019
Nuformix Achieves 2nd NXP001 Development Milestone
May 15, 2019
Strategic Cannabinoid Agreement
April 9, 2019
Notification Major Share Interests
April 5, 2019
Nuformix Commences NXP001 Clinical Trial
March 22, 2019
MHRA approval for NXP001
February 27, 2019
Unaudited Half Year Results
December 20, 2018
Reports Results from Novel IPF Pre-Clinical Trial
December 3, 2018
Expansion of NXP001 Agreement & Milestone Payment
November 27, 2018
Additional New NXP002 Patent Filing
September 28, 2018
NXP001 Pre-Clinical Milestone Achieved
September 14, 2018
Convertible Loan Amendment
August 28, 2018
Annual Report and Notice of AGM
August 16, 2018
Collaboration with SGSC
June 26, 2018
Dr Chris Blackwell Appointed NED
May 11, 2018
Stmnt re Share Price Movement
April 11, 2018
Update re: Broker
March 2, 2018
NXP002 Pilot Study in Lung and Liver Fibrosis
January 31, 2018
Agreement to License NXP001
December 15, 2017
Dr Andy Richards Chairs Advisory Panel - New Appts
December 14, 2017
Grant of Warrants
December 6, 2017
NXP001 agreement for pilot bioequivalence study
October 19, 2017
Admission and First Dealings
October 16, 2017
Change of Name
October 13, 2017
Final Results and Annual Report
September 22, 2017
Prospectus re: Proposed Acquisition of Nuformix
September 15, 2017
Convertible Loan Agreement
April 20, 2017
Accounts for the period ended 31 March 2016
September 21, 2016
Possible Acquisition and Suspension of Trading
September 16, 2016
Half Yearly Report
March 29, 2016
Broker Appointment and Corporate Update
February 24, 2016
Publication of Prospectus and First Dealings
December 17, 2015